Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CANCER TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 EPIDEMOLOGY
6 AUSTRALIA CANCER TREATMENT MARKET: REGULATORY SCENARIO
6.1 TIMELINE TO APPROVE A DRUG
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING CANCER BURDEN WORLDWIDE
7.1.2 GROWING GERIATRIC POPULATION
7.1.3 AVAILABILITY OF DIFFERENT TYPES OF TARGETED THERAPIES
7.1.4 RISING NUMBER OF FDA APPROVAL
7.1.5 GROWING R&D ACTIVITIES
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS
7.2.2 HIGH COST OF CANCER TREATMENT
7.2.3 LACK OF EARLY DETECTION
7.3 OPPORTUNITIES
7.3.1 STRATEGIC DEVELOPMENT AMONG MAJOR PLAYERS
7.3.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS
7.3.3 RISING EXPENDITURE ON CANCER TREATMENT
7.4 CHALLENGES
7.4.1 PATENT EXPIRY OF DRUGS
8 AUSTRALIA CANCER TREATMENT MARKET, BY CANCER TYPE
8.1 OVERVIEW
8.2 BREAST CANCER
8.3 COLORECTAL CANCER WITH LIVER METASTASES
8.4 LUNG CARCINOMA
8.5 PROSTATE CANCER
8.6 OVARIAN CANCER
8.7 HEAD-AND-NECK CANCER
8.8 PANCREATIC CANCER
8.9 GLIOBLASTOMA
8.1 RENAL CELL CARCINOMA
8.11 ANAPLASTIC THYROID CARCINOMA
8.12 SARCOMA
9 AUSTRALIA CANCER TREATMENT MARKET, BY TREATMENT
9.1 OVERVIEW
9.2 MEDICATION
9.2.1 BY DRUG TYPE
9.2.1.1 lung carcinoma
9.2.1.1.1 Nivolumab (Opdivo)
9.2.1.1.2 Bevacizumab (Avastin)
9.2.1.1.3 Crizotinib (Xalkori)
9.2.1.1.4 Erlotinib (Tarceva)
9.2.1.1.5 Gefitinib (Iressa)
9.2.1.1.6 Afatinib Dimaleate (Gilotrif)
9.2.1.1.7 Ceritinib (Ldk378/Zykadia)
9.2.1.1.8 Ramucirumab (Cyramza)
9.2.1.1.9 others
9.2.1.2 Colorectal Cancer with Liver Metastases
9.2.1.2.1 Nivolumab (Opdivo)
9.2.1.2.2 Cetuximab (Erbitux)
9.2.1.2.3 Panitumumab (Vectibix)
9.2.1.2.4 Bevacizumab (Avastin)
9.2.1.2.5 Ziv-Aflibercept (Zaltrap)
9.2.1.2.6 Regorafenib (Stivarga)
9.2.1.2.7 Ramucirumab (Cyramza)
9.2.1.2.8 Ipilimumab (Yervoy)
9.2.1.2.9 Encorafenib (Braftovi)
9.2.1.2.10 Pembrolizumab (Keytruda)
9.2.1.2.11 others
9.2.1.3 ovarian cancer
9.2.1.3.1 Bevacizumab (Avastin)
9.2.1.3.2 Olaparib (Lynparza)
9.2.1.3.3 Rucaparib Camsylate (Rubraca)
9.2.1.3.4 Niraparib Tosylate Monohydrate (Zejula)
9.2.1.3.5 others
9.2.1.4 head-and-neck cancer
9.2.1.4.1 Cetuximab (Erbitux)
9.2.1.4.2 Pembrolizumab (Keytruda)
9.2.1.4.3 Nivolumab (Opdivo)
9.2.1.4.4 others
9.2.1.5 renal cell carcinoma
9.2.1.5.1 Nivolumab (Opdivo)
9.2.1.5.2 Bevacizumab (Avastin)
9.2.1.5.3 Sorafenib (Nexavar)
9.2.1.5.4 Sunitinib (Sutent)
9.2.1.5.5 Pazopanib (Votrient)
9.2.1.5.6 Temsirolimus (Torisel)
9.2.1.5.7 Everolimus (Afinitor)
9.2.1.5.8 Axitinib (Inlyta)
9.2.1.5.9 Cabozantinib (Cabometyx)
9.2.1.5.10 others
9.2.1.6 anaplastic thyroid carcinoma
9.2.1.6.1 Cabozantinib (Cometriq)
9.2.1.6.2 Vandetanib (Caprelsa)
9.2.1.6.3 Sorafenib (Nexavar)
9.2.1.6.4 Lenvatinib Mesylate (Lenvima)
9.2.1.6.5 Trametinib (Mekinist)
9.2.1.6.6 Dabrafenib (Tafinlar)
9.2.1.6.7 Selpercatinib (Retevmo)
9.2.1.6.8 Pralsetinib (Gavreto)
9.2.1.6.9 others
9.2.1.7 breast cancer
9.2.1.7.1 Everolimus (Afinitor)
9.2.1.7.2 Tamoxifen (Nolvadex)
9.2.1.7.3 Trastuzumab (Herceptin)
9.2.1.7.4 Fulvestrant (Faslodex)
9.2.1.7.5 Anastrozole (Arimidex)
9.2.1.7.6 Exemestane (Aromasin)
9.2.1.7.7 Letrozole (Femara)
9.2.1.7.8 Pertuzumab (Perjeta)
9.2.1.7.9 Palbociclib (Ibrance)
9.2.1.7.10 Ribociclib (Kisqali)
9.2.1.7.11 Tosylate (Talzenna)
9.2.1.7.12 Pembrolizumab (Keytruda)
9.2.1.7.13 Margetuximab-Cmkb (Margenza)
9.2.1.7.14 others
9.2.1.8 prostate cancer
9.2.1.8.1 Cabazitaxel (Jevtana)
9.2.1.8.2 Enzalutamide (Xtandi)
9.2.1.8.3 Abiraterone Acetate (Zytiga)
9.2.1.8.4 Radium 223 Dichloride (Xofigo)
9.2.1.8.5 Apalutamide (Erleada)
9.2.1.8.6 Darolutamide (Nubeqa)
9.2.1.8.7 Rucaparib Camsylate (Rubraca)
9.2.1.8.8 Olaparib (Lynparza)
9.2.1.8.9 others
9.2.1.9 pancreatic cancer
9.2.1.9.1 Erlotinib (Tarceva)
9.2.1.9.2 Everolimus (Afinitor)
9.2.1.9.3 Sunitinib (Sutent)
9.2.1.9.4 Olaparib (Lynparza)
9.2.1.9.5 Belzutifan (Welireg)
9.2.1.9.6 others
9.2.1.10 glioblastoma
9.2.1.10.1 Bevacizumab (Avastin)
9.2.1.10.2 Everolimus (Afinitor)
9.2.1.10.3 Belzutifan (Welireg)
9.2.1.10.4 others
9.2.1.11 sarcoma
9.2.1.11.1 Cosmegen (Dactinomycin)
9.2.1.11.2 Dactinomycin
9.2.1.11.3 Doxorubicin Hydrochloride
9.2.1.11.4 Eribulin Mesylate
9.2.1.11.5 Gleevec (Imatinib Mesylate)
9.2.1.11.6 Halaven (Eribulin Mesylate)
9.2.1.11.7 Imatinib Mesylate
9.2.1.11.8 Pazopanib Hydrochloride
9.2.1.11.9 Tazemetostat Hydrobromide
9.2.1.11.10 Tazverik (Tazemetostat Hydrobromide)
9.2.1.11.11 Trabectedin
9.2.1.11.12 Votrient (Pazopanib Hydrochloride)
9.2.1.11.13 Yondelis (Trabectedin)
9.2.1.11.14 others
9.2.2 BY VACCINES
9.2.2.1 Cervarix
9.2.2.2 Gardasil
9.2.2.3 Gardasil-9
9.2.2.4 Hepatitis B (Hbv) Vaccine (Heplisav-B)
9.2.2.5 Sipuleucel-T (Provenge)
9.2.2.6 others
9.3 RADIOTHERAPY
9.3.1 EXTERNAL BEAM RADIATION THERAPY
9.3.1.1 Three -Dimensional Confromal Radiation Therapy (3-D CRT)
9.3.1.2 Proton Therapy
9.3.1.3 Intensity-Modulated Radiation Therapy (IMRT)
9.3.1.4 Image-Guided Radiation Therapy (IGRT)
9.3.1.5 Tomotherapy
9.3.1.6 Stereotactic Radiosurgery
9.3.1.7 Stereotactic Body Radiation Therapy (SRT)
9.3.1.8 Intraoperative Radiation Therapy
9.3.1.9 others
9.3.2 INTERNAL RADIATION THERAPY (BRACHYTHERAPY)
9.3.2.1 low-dose-rate (LDR) brachytherapy
9.3.2.2 high-dose-rate (HDR) brachytherapy
9.3.3 SYSTEMIC RADIATION THERAPY
9.3.3.1 peptide receptor radionuclide therapy (PRRT)
9.3.3.2 others
9.4 SURGERY
9.4.1 PAROTIDECTOMY
9.4.2 ENDOSCOPIC SURGERY
9.4.3 NECK DISSECTION
9.4.4 RECONSTRUCTIVE SURGERY
9.4.5 OTHERS
9.5 TARGETED THERAPIES
9.5.1 SMALL MOLECULES
9.5.1.1 tyrosine & serine/threonine kinases
9.5.1.1.1 imatinib (gleevec)
9.5.1.1.2 gefitinib (iressa)
9.5.1.1.3 erlotinib (tarceva)
9.5.1.1.4 sunitinib (sutent)
9.5.1.1.5 perifosine
9.5.1.1.6 others
9.5.1.2 proteosomes
9.5.1.2.1 bortezomib (velcade)
9.5.1.2.2 carfilzomib (kyprolis)
9.5.1.2.3 marizomib
9.5.1.3 MMPS and HSPS
9.5.1.3.1 batimastat
9.5.1.3.2 neovastat
9.5.1.3.3 prinomastat
9.5.1.3.4 rebimastat
9.5.1.3.5 ganetespib
9.5.1.3.6 others
9.5.1.4 apoptosis
9.5.1.4.1 obatoclax
9.5.1.4.2 navitoclax
9.5.1.4.3 others
9.5.2 IMMUNOTHERAPY
9.5.2.1 immune checkpoint inhibitors
9.5.2.2 T-cell transfer therapy
9.5.2.2.1 TIL therapy
9.5.2.2.2 car T-cell therapy
9.5.2.2.3 by product
9.5.2.2.3.1 tisagenlecleucel (kymriah)
9.5.2.2.3.2 axicabtagene ciloleucel (yescarta)
9.5.2.2.3.3 brexucabtagene autoleucel (tecartus)
9.5.2.2.3.4 others
9.5.2.2.4 by technology
9.5.2.2.4.1 autologous
9.5.2.2.4.2 allogeneic
9.5.2.3 monoclonal antibodies
9.5.2.3.1 rituximab
9.5.2.3.2 blinatumomab (blincyto)
9.5.2.3.3 others
9.5.2.4 immune system modulators
9.5.2.4.1 cytokines
9.5.2.4.2 interferons (INFS)
9.5.2.4.3 interleukins (ILS)
9.5.2.4.4 hematopoietic growth factors
9.5.2.4.5 BCG
9.5.2.4.6 immunomodulatory drugs/biological response modifiers
9.5.2.4.7 thalidomide (thalomid)
9.5.2.4.8 lenalidomide (revlimid)
9.5.2.4.9 pomalidomide (pomalyst)
9.5.2.4.10 imiquimod (aldara, zyclara)
9.5.2.4.11 OTHERS
9.5.2.5 treatment vaccines
9.5.2.6 others
9.5.3 HORMONAL THERAPY
9.5.3.1 signal transduction inhibitors
9.5.3.2 gene expression modulators
9.5.3.3 apoptosis inducers
9.5.3.4 angiogenesis inhibitors
9.5.3.5 gene therapy
9.5.3.6 others
9.6 OTHERS
10 AUSTRALIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 INJECTABLE
10.3 ORAL
10.4 OTHERS
11 AUSTRALIA CANCER TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
12 AUSTRALIA CANCER TREATMENT MARKET, BY REGION
12.1 AUSTRALIA
13 AUSTRALIA CANCER TREATMENT MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: AUSTRALIA
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 DIFFERENCES IN APPROVAL TIMES BETWEEN EMEA AND FDA FOR SELECTED TARGETED THERAPIES SINCE 2001
TABLE 2 NEW CANCER CASES, AGES 85+ IN THE U.S.
TABLE 3 DEATH CAUSES DUE TO CANCER, AGES 85+ IN THE U.S.
TABLE 4 HERE ARE SOME STATISTICS RELATED TO THE TREATMENT COST:
TABLE 5 AUSTRALIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 6 AUSTRALIA BREAST CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 AUSTRALIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 AUSTRALIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 AUSTRALIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 AUSTRALIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 AUSTRALIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 AUSTRALIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 AUSTRALIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 AUSTRALIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 AUSTRALIA SARCOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 AUSTRALIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 18 AUSTRALIA MEDICATION IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 AUSTRALIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 20 AUSTRALIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 21 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 22 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 23 AUSTRALIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 24 AUSTRALIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 25 AUSTRALIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 26 AUSTRALIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 27 AUSTRALIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 28 AUSTRALIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 29 AUSTRALIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 30 AUSTRALIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 31 AUSTRALIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 32 AUSTRALIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 33 AUSTRALIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 AUSTRALIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 35 AUSTRALIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 36 AUSTRALIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 37 AUSTRALIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 38 AUSTRALIA SURGERY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 AUSTRALIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 40 AUSTRALIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 AUSTRALIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 42 AUSTRALIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 43 AUSTRALIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 44 AUSTRALIA PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 45 AUSTRALIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 46 AUSTRALIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 47 AUSTRALIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 48 AUSTRALIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 49 AUSTRALIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 50 AUSTRALIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 51 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 52 AUSTRALIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 AUSTRALIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 54 AUSTRALIA OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 55 AUSTRALIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 56 AUSTRALIA INJECTABLE IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 57 AUSTRALIA ORAL IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 58 AUSTRALIA OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 59 AUSTRALIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 60 AUSTRALIA HOSPITALS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 61 AUSTRALIA SPECIALTY CLINICS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 62 AUSTRALIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 63 AUSTRALIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 64 AUSTRALIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 65 AUSTRALIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 66 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 67 AUSTRALIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 68 AUSTRALIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 69 AUSTRALIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 70 AUSTRALIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 71 AUSTRALIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 72 AUSTRALIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 73 AUSTRALIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 74 AUSTRALIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 75 AUSTRALIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 76 AUSTRALIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 AUSTRALIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 78 AUSTRALIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 79 AUSTRALIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 80 AUSTRALIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 81 AUSTRALIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 82 AUSTRALIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 83 AUSTRALIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 84 AUSTRALIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 85 AUSTRALIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 86 AUSTRALIA PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 87 AUSTRALIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 88 AUSTRALIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 89 AUSTRALIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 90 AUSTRALIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 91 AUSTRALIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 92 AUSTRALIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 93 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 94 AUSTRALIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 95 AUSTRALIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 96 AUSTRALIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 97 AUSTRALIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 2 AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: AUSTRALIA VS REGIONAL MARKET ANALYSIS
FIGURE 5 AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 8 AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 9 HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 10 BREAST CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN 2022 TO 2029
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AUSTRALIA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET
FIGURE 12 ESTIMATED NUMBER OF NEW CASES AND DEATHS BY VARIOUS TYPES OF CANCER WORLDWIDE, 2020
FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 14 AUSTRALIA CANCER TREATMENT MARKET: BY CANCER TYPE, 2021
FIGURE 15 AUSTRALIA CANCER TREATMENT MARKET: BY CANCER TYPE, 2020-2029 (USD MILLION)
FIGURE 16 AUSTRALIA CANCER TREATMENT MARKET: BY CANCER TYPE, CAGR (2022-2029)
FIGURE 17 AUSTRALIA CANCER TREATMENT MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 18 AUSTRALIA CANCER TREATMENT MARKET: BY TREATMENT, 2021
FIGURE 19 AUSTRALIA CANCER TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 20 AUSTRALIA CANCER TREATMENT MARKET: BY TREATMENT CAGR (2022-2029)
FIGURE 21 AUSTRALIA CANCER TREATMENT MARKET: BY TREATMENT LIFELINE CURVE
FIGURE 22 AUSTRALIA CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 23 AUSTRALIA CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 24 AUSTRALIA CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 25 AUSTRALIA CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION LIFELINE CURVE
FIGURE 26 AUSTRALIA CANCER TREATMENT MARKET: BY END USER, 2021
FIGURE 27 AUSTRALIA CANCER TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 28 AUSTRALIA CANCER TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 AUSTRALIA CANCER TREATMENT MARKET: BY END USER LIFELINE CURVE
FIGURE 30 AUSTRALIA CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)
